Valsartan cuts stroke in high-risk hypertensives in KYOTO HEART trial
Links shared publicly online about this topic.
- 1,780total visits
Valsartan cuts stroke in high-risk hypertensives in KYOTO HEART trial
Despite showing an impressive 45% reduction in stroke with valsartan add-on therapy compared with non-ARB add-on treatment in high-risk hypertensive patients in Japan, the findings of the KYOTO HEART study are not strong enough to support ARB use as first-line therapy in Western populations, say expert observers.
View full resource at theheart.org
Tags: Heart, Heart Disease, High Blood Pressure, High Blood Pressure Medication, Stroke, Thrombotic Event, Diovan
Most Recently Shared on September 1, 2009 at 3:26 pm By:
heartwire: KYOTO HEART study not quite sufficient to extend the role of ARBs to first-line therapy http://bit.ly/uasES #ESC09
Advertisement
